Tuesday, March 24, 2026
Home Tags Zydus Lifesciences

Tag: Zydus Lifesciences

Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India
Brands in Conversation

Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India

Author -
0
Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India
Brands in Conversation

Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India

Author -
0
Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy
Brands in Conversation

Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy

Author -
0
Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India
Brands in Conversation

Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India

Author -
0
Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
Brands in Conversation

Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada

Author -
0
Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
Brands in Conversation

Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial

Passionate in Marketing -
0
Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
Brands in Conversation

Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial

Passionate in Marketing -
0
Zydus’ Amplitude receives CE mark for its robotic surgical system ‘Andy’
Brands in Conversation

Zydus’ Amplitude receives CE mark for its robotic surgical system ‘Andy’

Passionate in Marketing -
0
Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia
Brands in Conversation

Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia

Author -
0
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg
Brands in Conversation

Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg

Author -
0
123Page 1 of 3

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

ABOUT US

Passionate in Marketing is promoted by i-miRa Knowledge Solutions, a company founded in 2010 to foster various business units dedicated to creating, disseminating, and managing knowledge-based products, services, and solutions. These offerings cater to corporate entities, startups, and academic institutions alike.

Contact : [email protected]

FOLLOW US

© 2026 | Passionate In Marketing |All Rights Reserved | Privacy Policy